Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Gliosarcoma 1Glioblastoma 1

Interventions

Temozolomide 23Radiotherapy 15Radiation 7Bevacizumab 6temsirolimus 5Sirolimus 5Radiotherapy, Conformal 5Erlotinib Hydrochloride 5Carmustine 5Carboplatin 5Radiotherapy, Intensity-Modulated 4Everolimus 4Vorinostat 3Irinotecan 3veliparib 2tipifarnib 2plerixafor 2pembrolizumab 2atezolizumab 2Surgical Procedures, Operative 2Sorafenib 2Gefitinib 2Fluorodeoxyglucose F18 2Cilengitide 2Chemotherapy, Adjuvant 2vatalanib 1vandetanib 1terameprocol 1tandutinib 1romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Gliosarcoma × motexafin gadolinium × Clear all
NCT00305864 2018-03-05

Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

National Cancer Institute (NCI)

Phase 1/2 Completed
118 enrolled 10 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡